Thymosin Alpha-1

Safety Risk (1.2/5.0). Exceptionally clean safety profile. The TESTS Phase 3 trial (n=1,106, double-blind, placebo-controlled) showed adverse event rates indistinguishable from placebo (66.4% vs 67.6%, P=0.70). No drug-related serious adverse events in any trial across >11,000 subjects. Catastrophic risk screen: NEGATIVE. No documented life-threatening, permanent, or fatal adverse events from the molecule itself across all published literature. The BioHarmony catastrophic floor does not trigger. FDA FAERS shows no signal. The only genuine intrinsic theoretical risk is autoimmune flare in patients with pre-existing autoimmune conditions, which is why the Avoid-if section specifically flags active autoimmune disease, immunosuppressive therapy, and transplant status. This is one of the cleanest safety profiles in the entire peptide class, cleaner than BPC-157 in terms of human RCT exposure volume.

Side Effect Profile (1.5/5.0). Mild injection site reactions (redness, minor discomfort) are the most commonly reported side effect in controlled trials. Occasional transient flu-like symptoms at treatment initiation, usually resolving within 24-48 hours. No systemic side effects have been reliably attributed to TA-1 in controlled trials beyond local injection-site effects. The side effect profile is essentially comparable to saline placebo per the TESTS Phase 3 delta. No tolerance buildup, no rebound effects on cessation, and no pattern of emergent long-tail AEs across 25+ years of commercial Zadaxin use in the 37 countries where the drug is approved. Community anecdotal reports match trial data closely: "injection stings a little, sometimes mild fatigue on day one, nothing concerning."

Financial Cost (2.5/5.0). Under v0.5 accessible-channel scoring rules, US patients source TA-1 through 503A or 503B compounding pharmacies at approximately $100-400/month for the 1.6 mg 2x/week protocol. The Zadaxin brand (SciClone) is not available in the US and runs approximately $600+/month internationally (Italy, China). Research peptide vendors are cheaper but carry quality and purity concerns that do not reflect the intrinsic cost of the molecule and therefore do not count toward the score. Not covered by insurance for off-label immune optimization. Modestly costly for a chronic-use intervention; typical stack contribution sits in the $100-200/month working range for most users. This prices above OTC supplements like astaxanthin or magnesium but below prescription pharmaceuticals like semaglutide or rapamycin on a typical monthly basis.

Time/Effort Burden (2.0/5.0). Twice-weekly subcutaneous injections. Each injection takes 2-3 minutes including reconstitution of lyophilized peptide, drawing up with a 27-30G insulin syringe, site prep, and injection. No oral bioavailability (peptide degradation in the gut rules out meaningful systemic absorption without encapsulation technology not present in current products), so injection is the only effective route. Intranasal and oral lozenge gray-market forms are functionally placebo at current formulation technology. For users comfortable with self-injection (diabetics, other peptide users, fertility patients), the friction is low. For injection-averse users, this is a real behavioral hurdle. Compared to oral supplements, TA-1 sits at a higher effort floor. Compared to daily GLP-1 or CJC-1295/ipamorelin injection protocols, TA-1's twice-weekly cadence is much lighter.

Opportunity Cost (1.5/5.0). TA-1 complements virtually every other immune support intervention. Can be stacked with other peptides (BPC-157 for soft-tissue repair plus immune modulation, TB-500, KPV), supplements (vitamin D, zinc, elderberry, Nutrient supplement categories), and lifestyle interventions (sleep, exercise, stress management). No meaningful displacement of better interventions. The only real opportunity cost concern is when someone uses TA-1 as a substitute for basic immune fundamentals (sleep quality, fiber intake, stress management, aerobic fitness) rather than as an adjunct. For the indicated population (age-related immune decline, post-illness recovery, cancer adjuvant, travel prophylaxis), there is no better intervention in the peptide class for this specific effect profile, which means the opportunity cost is essentially zero.

Dependency/Withdrawal (1.2/5.0). No adaptation, tolerance, or rebound immunosuppression documented across 25+ years of clinical use. The immune education mechanism means benefits can persist after cessation; virologic responses in hepatitis B continue to accrue up to 12 months after treatment ends per Iino 2007's delayed-response pattern. No withdrawal syndrome has been reported in any RCT or community use. No receptor desensitization because TA-1 works upstream of TLR9/NF-kB signaling without chronic receptor occupation. Per v0.5 dependency framework, this sits near the peptide-class floor, functionally identical to BPC-157 and short-course peptide protocols. Users can start, stop, or cycle TA-1 without penalty, a meaningful advantage over functional-dependency interventions like thyroid hormone, HRT, or GLP-1 agonists.

Reversibility (1.2/5.0). Fully reversible. Stop the injections and exogenous TA-1 clears within hours (approximately 2-hour plasma half-life per Tuthill 2000). The immune reprogramming effects gradually fade over weeks to months, returning the immune phenotype to the patient's pre-treatment baseline without permanent changes. No epigenetic imprints, no structural thymic modification, no receptor downregulation, and no HPA axis recalibration. Contrast with pharmaceutical interventions where cessation drives rebound (GLP-1 agonists and weight regain, SSRIs and discontinuation syndrome, benzodiazepines and withdrawal seizures): TA-1 cessation produces only a gradual asymptotic return to pre-treatment immune tone over 4-12 weeks. This is structurally identical to the reversibility profile of vaccines, vitamins, and other immune-education interventions that train the system and then step out cleanly.